Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Johansson Jan Erik) > (2015-2019) > Quality of Life aft...

Johansson, EvaUppsala universitet,Urologkirurgi (författare)

Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.

Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

Elsevier BV,2018

Nummerbeteckningar

LIBRIS-ID:oai:gup.ub.gu.se/288386
https://gup.ub.gu.se/publication/288386URI
https://doi.org/10.1016/j.euo.2018.03.003DOI
http://kipublications.ki.se/Default.aspx?queryparsed=id:145300684URI
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-158093URI

Kompletterande språkuppgifter

Språk:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Manuscript title: Quality of life after radical prostatectomy or watchful waiting with or without androgen deprivation therapy: The Scandinavian Prostate Cancer Group-4 Randomized Trial
Men with prostate cancer experience adjuvant androgen deprivation therapy (ADT) differently.To evaluate the effect of ADT on quality of life (QoL), patients' experience of clinical check-ups, and differences in cancer information as explanatory factors.A study-specific questionnaire was sent to all men randomized in the SPCG-4 trial to radical prostatectomy (RP) or watchful waiting (WW) still alive (400/695) and a control group of 281 men.ADT.Self-assessed QoL, worry at clinical check-ups, and amount of information received. Estimated relative risks with associated 95% confidence intervals (CI) for risk comparisons between groups using a log-binomial regression.The SPCG-4 men had median follow-up of 12.2 yr and median age of 77.0 yr; 26% in the RP group and 40% in the WW group received ADT treatment. High QoL for men without ADT was 36% for the RP group, 44% for the WW group, and 45% for the control group. High QoL for men with ADT was 30% for the RP group and 20% for the WW group. Among men with ADT, those in the WW group received significantly less information about the disease than men in the RP group. Receiving no or little information about prostate cancer was reported by 17% of patients in the RP group and 39% in the WW group among men receiving ADT (relative risk 0.44, 95% CI 0.22-0.89). At clinical check-ups, men treated with ADT had significantly higher levels of worry, regardless of study group, than men without ADT. Limitations include the lack of longitudinal data and a low number of men receiving ADT in the RP group.Men on WW without ADT reported high QoL comparable to that for men without prostate cancer. ADT treatment in the WW group was associated with the lowest scores for all psychological parameters, and these men reported that they were least informed about prostate cancer and its consequences.Good communication and information from caregivers are associated with less negative psychological effects at prostate cancer progression.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Urologi och njurmedicin hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Urology and Nephrology hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
Aged
Androgen Antagonists
therapeutic use
Finland
Humans
Male
Middle Aged
Models
Statistical
Prostatectomy
Prostatic Neoplasms
psychology
therapy
Quality of Life
psychology
Surveys and Questionnaires
Sweden
Treatment Outcome
Watchful Waiting
Prostate cancer

Biuppslag (personer, institutioner, konferenser, titlar ...)

Steineck, Gunnar,1952Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Klinisk cancer epidemiologi, Stockholm, Göteborg(Swepub:gu)xstegu (författare)
Holmberg, LarsUppsala universitet,Endokrinkirurgi,Division of Cancer Studies, Medical School, King's College London, London, UK.(Swepub:uu)larsholmb (författare)
Johansson, Jan-ErikUrologiska Kliniken, Örebro (författare)
Nyberg, TommyKarolinska Institutet,Klinisk cancer epidemiologi, Stockholm (författare)
Bill-Axelson, AnnaUppsala universitet,Urologkirurgi(Swepub:uu)anbil030 (författare)
Uppsala universitetUrologkirurgi (creator_code:org_t)

Sammanhörande titlar

Ingår i:European urology oncology: Elsevier BV1:2, s. 134-1422588-9311

Internetlänk

Hitta via bibliotek

European urology oncology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Johansson, Eva; Steineck, Gunnar ...; Holmberg, Lars; Johansson, Jan-E ...; Nyberg, Tommy; Bill-Axelson, An ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Urologi och njur ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: European urology ...

Av lärosätet: Göteborgs universitet; Karolinska Institutet; Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se